The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Meglumine antimoniate, commercialized as Glucantime, is the most common treatment for leishmaniasis over the last 70 years. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection. The active ingredient in treating leishmaniasis is believed to be antimonite Sb(III) after in vivo reduction of antimoniate Sb(V).